Niederwieser, Christian http://orcid.org/0000-0002-0114-1011
Iacobelli, Simona
Franke, Georg-Nikolaus http://orcid.org/0000-0001-8239-002X
Koster, Linda
van Os, Marleen
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Hübel, Kai
Scheid, Christof
Müller, Lutz Peter http://orcid.org/0000-0002-2212-8166
Stelljes, Matthias
Morozova, Elena http://orcid.org/0000-0002-9605-485X
Passweg, Jakob http://orcid.org/0000-0001-7092-3351
Onida, Francesco
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Saccardi, Riccardo
Ladetto, Marco
Salmenniemi, Urpu
Bethge, Wolfgang http://orcid.org/0000-0001-6052-2618
Poiré, Xavier
Kobbe, Guido
McLornan, Donal P. http://orcid.org/0000-0003-1224-091X
Robin, Marie http://orcid.org/0000-0003-1388-9876
Kröger, Nicolaus http://orcid.org/0000-0002-2961-4183
Funding for this research was provided by:
AbbVie Inc. | AbbVie Deutschland
Celgene
Janssen Pharmaceuticals
Bristol-Myers Squibb Foundation
Novartis
Jazz Pharmaceuticals
Jazz, Curin, Geron
Pfizer
Gilead Sciences
Amgen
Neovii
AstraZeneca
Gilead Foundation
Miltenyi Biotec
Roche
Beigene, Riemser
Medac
Novartis | Novartis Pharma
AbbVie
CTI
AbbVie Inc. | AbbVie Biotherapeutics
Medac, Astex
Article History
Received: 2 January 2024
Revised: 3 April 2024
Accepted: 5 April 2024
First Online: 25 April 2024
Competing interests
: The study was funded in part by Pierre Fabre. NK received an honorarium from Novartis, Neovii, Riemser, and BMS. PD consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi, Novartis, Riemser; speakers’ bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Novartis, Riemser, Roche; research support from Riemser (all to institution). WB received Honoraries and Travel Grants from Medac, Miltenyi, BMS, Janssen, and Novartis. MR received research funding (independent studies) from AbbVie, Novartis, Medac, and Astex. LPM received an honorarium from Pfizer, Gilead Novartis, Amgen, Jazz, and Neovii.KH received research support from Celgene/BMS, Gilead, Incyte, Janssen, Roche, and Sanofi and honorarium from AbbVie, EUSA Pharma, Gilead, Incyte, Novartis, Roche, Beigene, Celgene/BMS, EUSA Pharma, Incyte, Roche, Sanofi. UP received honoraria from Abbvie, Celgene/Jazz, Curis, Geron, and Janssen for consulting or advisory roles from BMS GmbH & Co KG, Celgene/Jazz, and Novartis, research funding from Amgen, BerGenBio, Celgene, Curis, Janssen, and Novartis, and travel sponsoring, accommodations, and expenses from Celgene. DPM received honoraria/consultation fees from Novartis, Jazz Pharma, and partial participation in a company-sponsored bureau (AbbVie, CTI).